Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalteparin for VTE prevention in lower extremity fractures
NCT00187408Phase 4Completed
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Aug 2002
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in venous thromboembolism (VTE) comparing Dalteparin with Placebo (2 arms). Primary endpoint: Clinically important venous thromboembolism at 3 months. Started Aug 2002; status: completed.
02
Drugs
dalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00187408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00187408.